Categories: News

MIM Software Inc. Announces FDA 510(k) Clearance for AI Segmentation and New Single Timepoint Dosimetry Capability for Molecular Radiotherapy

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CLEVELAND, Nov. 17, 2021 /PRNewswire/ — MIM Software Inc., a leading global provider of medical imaging software, announced today new innovations to MIM SurePlan™ MRT, its software package for Molecular Radiotherapy.

MIM SurePlan MRT has received 510(k) clearance from the U.S. Food and Drug Administration for new AI segmentation models, which simplify the contouring process for dosimetry. AI segmentation provides significant time savings and enhanced results compared to manual and atlas-based segmentation. MIM Software’s AI segmentation models can be deployed locally or through the cloud.

“We understand the challenges that are commonly faced when implementing clinical dosimetry,” said Tim Adams, Nuclear Medicine Market Director at MIM Software. “AI segmentation is one of the technologies needed to make clinical dosimetry practical.  Most deployments of AI utilize cloud infrastructures and demand laborious legal agreements for the technologies to be used. However, we have made it easier for all clinics to access it by offering segmentation models in the cloud and locally.”

In addition, MIM SurePlan MRT now includes two single time point methods – the Hänscheid approach and the prior-information approach.

The Hänscheid approach uses a single SPECT/CT acquired around a carefully chosen time after each cycle of therapy to calculate the absorbed dose. The prior information approach uses time-activity curve information from multiple SPECT/CTs after the first cycle to calculate the dose for the remaining cycles, using only a single SPECT/CT at each of the remaining cycles.

MIM Software will demonstrate its new AI segmentation models in the AI Showcase at the RSNA 2021 Scientific Assembly and Annual Meeting in Chicago (November 28-December 1). MIM Software will also demonstrate MIM SurePlan MRT in booth #6327.

About MIM Software Inc.
MIM Software Inc. is a privately held company with a dynamic working environment. It is headquartered in Cleveland, OH, with international offices in Beijing, Chengdu, and Brussels. These fully-staffed offices manage application support as well as sales and engineering efforts for the European and Asian markets, respectively.

MIM Software sells its products globally to imaging centers, hospitals, specialty clinics, research organizations, and pharmaceutical companies. The company’s products are used in over 3000 centers worldwide, with more than 500 of those centers located outside of the United States.

To learn more, visit www.mimsoftware.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mim-software-inc-announces-fda-510k-clearance-for-ai-segmentation-and-new-single-timepoint-dosimetry-capability-for-molecular-radiotherapy-301423219.html

SOURCE MIM Software Inc.

Staff

Recent Posts

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

3 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project as Federal Support for Blockchain Grows

Dr. Anosh Ahmed repurposes West Side warehouse into blockchain innovation center, targeting 250+ jobs and…

3 hours ago

Dr. Anosh Ahmed Advances Chicago Crypto Hub Project Amid National Pro-Crypto Policy Shift

Dr. Anosh Ahmed converts vacant West Side warehouse into blockchain innovation hub, creating 250+ jobs…

3 hours ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits…

3 hours ago

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation…

3 hours ago

Nixol Capsules Launch in the UK: A Natural Path to Weight Management and Metabolic Support

Nixol introduces a new natural supplement in the United Kingdom to support metabolism, curb cravings,…

3 hours ago